Literature DB >> 15914363

Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.

Ken Ishiyama1, Akiyoshi Takami, Hirokazu Okumura, Jun Ozaki, Shigeru Shimadoi, Shin-ichi Yamanaka, Shinji Nakao.   

Abstract

We encountered a 53-year-old man with general fatigue. Bone marrow investigations revealed an infiltration of CD20+CD5+CD23- cells and the presence of cyclin D1 lymphoid cells, leading to a diagnosis of mantle cell lymphoma, clinical stage IV. The first 2 lines of chemotherapy, CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) and fludarabine-cyclophosphamide, produced only a transient decrease in serum lactic dehydrogenase levels, without a clinical remission. Because of the persistence of bone marrow hypoplasia, monotherapy with 375 mg/m2 rituximab was administered. The pancytopenia gradually improved, and a complete remission was obtained after 4 cycles of rituximab. The patient remains in complete remission 21 months after the third rituximab therapy for maintenance.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15914363     DOI： 10.1532/IJH97.04167

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  24 in total

1.  Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

Authors:  I F Khouri; M S Lee; J Romaguera; N Mirza; H Kantarjian; M Korbling; M Albitar; S Giralt; B Samuels; P Anderlini; J Rodriguez; B von Wolff; J Gajewski; F Cabanillas; R Champlin
Journal:  Ann Oncol       Date:  1999-11       Impact factor: 32.976

2.  Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

Authors:  J M Foran; D Cunningham; B Coiffier; P Solal-Celigny; F Reyes; M Ghielmini; P W Johnson; C Gisselbrecht; M Bradburn; J Matthews; T A Lister
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

Authors:  J D Hainsworth; H A Burris; L H Morrissey; S Litchy; D C Scullin; J D Bearden; P Richards; F A Greco
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).

Authors:  N Niitsu; M Okamoto; Y Kuraishi; S Nakamura; F Kodama; M Hirano
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

6.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Authors:  Orion M Howard; John G Gribben; Donna S Neuberg; Michael Grossbard; Christina Poor; Milos J Janicek; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

Authors:  T Igarashi; Y Kobayashi; M Ogura; T Kinoshita; T Ohtsu; Y Sasaki; Y Morishima; T Murate; M Kasai; N Uike; M Taniwaki; Y Kano; K Ohnishi; Y Matsuno; S Nakamura; S Mori; Y Ohashi; K Tobinai
Journal:  Ann Oncol       Date:  2002-06       Impact factor: 32.976

8.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

Authors:  J Mangel; H A Leitch; J M Connors; R Buckstein; K Imrie; D Spaner; M Crump; N Pennell; A Boudreau; N L Berinstein
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

10.  A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.

Authors:  R I Fisher; S Dahlberg; B N Nathwani; P M Banks; T P Miller; T M Grogan
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113
View more
  1 in total

1.  Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Authors:  Lapo Alinari; Valerie L White; Christian T Earl; Timothy P Ryan; Jeffrey S Johnston; James T Dalton; Amy K Ferketich; Raymond Lai; David M Lucas; Pierluigi Porcu; Kristie A Blum; John C Byrd; Robert A Baiocchi
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.